RXi Pharmaceuticals announces positive results of intradermal injection for scar treatment

RXi Pharmaceuticals Corp. has announced positive interim results of an ongoing phase 2a study of RXI-109 treatment after scar revision surgery, according to a press release.

The results from a blinded panel and an investigator review showed that incision sites treated with RXI-109 after surgery achieved better scores compared with control incision sites in the same patients, 3 months after surgery.

Patients received six intradermal injections at either 5 mg/cm or 10 mg/cm beginning 2 weeks after scar revision surgery with the last dose given 3 months after surgery. Both doses of RXI-109 were equally well-tolerated with occasional transient redness and itching occurring in both doses.

The evaluation of the 15 patients available for follow-up included Physician and Observer Scar Assessment Scale (POSAS), Visual Analog Scale (VAS), a blinded assessment of photographs by the investigators and a blinded assessment by a panel separate from the investigators to review the same photographs.

The higher dose of 10 mg/cm did not appear to add clinical benefit compared with the 5 mg/cm dose. According to the release, the subsequent study cohorts will continue with a 5 mg/cm dose and have an evaluation through six months to further define the optimum treatment regimen.

Geert Cauwenbergh, MD, president and CEO of RXI Pharmaceuticals, presented data from the RXI-109 study at the Dawson James Securities Stock Growth Conference.